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http://www.biomedcentral.com/1471-2482/14/43RESEARCH ARTICLE Open AccessDoes recurrent laryngeal nerve lymph node
metastasis really affect the prognosis in
node-positive patients with squamous cell
carcinoma of the middle thoracic esophagus?
Jie Wu1*, Qi-Xun Chen1, Xing-Ming Zhou1, Wei-Ming Mao1 and Mark J Krasna2Abstract
Background: Recurrent laryngeal nerve (RLN) lymph node metastasis used to be shown a predictor for poor
prognosis in esophageal squamous cell carcinoma. The purpose of this study was to evaluate the prognostic
impact of RLN node metastasis and the number of metastatic lymph nodes in node-positive patients with
squamous cell carcinoma of middle thoracic esophagus.
Methods: A cohort of 235 patients who underwent curative surgery for squamous cell carcinoma of middle
thoracic esophagus was investigated. The prognostic impact was evaluated by univariate and multivariate analyses.
Results: Lymph node metastasis was found in 133 patients. Among them, 81 had metastatic RLN nodes, and 52
had at least one positive node but no RLN nodal involvement. The most significant difference in survival was
detected between patients with metastatic lymph nodes below and above a cutoff value of six (P < 0.001).
Multivariate analysis revealed that the number of metastatic lymph nodes was a significant factor associated with
overall survival (P < 0.001), but RLN lymph node metastasis was not (P = 0.865).
Conclusions: RLN Lymph node metastasis is not, but the number of metastatic nodes is a prognostic predictor in
node-positive patients with squamous cell carcinoma of the middle thoracic esophagus.
Keywords: Esophageal cancer, Lymph node metastasis, Recurrent laryngeal nerve, Squamous cell carcinomaBackground
In esophageal cancer, lymph node metastasis most likely
occurs on neck, mediastinum and abdomen. Recurrent
laryngeal nerve (RLN) lymph node is located at the
cervical base continuous to the upper mediastinum,
which is one of the most common sites of lymph node
metastasis in thoracic esophageal squamous cell car-
cinoma [1-4]. The clinical significance of RLN node
metastasis in surgical treatment of thoracic esophageal
squamous cell carcinoma has been discussed previ-
ously. Early metastasis [2,5], initial metastasis [6,7],
and even micrometastasis [7] of esophageal squamous
cell carcinoma often occur in RLN nodes. In addition,* Correspondence: wujiephd729@126.com
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reproduction in any medium, provided the ornodal involvement in RLN has been regarded as an
indication for three-field lymphadenectomy in the
surgical treatment of esophageal cancer [4,8-10]. More
importantly, RLN node metastasis has been shown to
be a strong predictor of poor prognosis in thoracic
esophageal squamous cell carcinoma [3,11].
However, some studies showed that the site of nodal
involvement was not associated with the prognosis of
thoracic esophageal squamous cell carcinoma, and the
number of metastatic lymph nodes had a greater prog-
nostic significance in thoracic esophageal squamous cell
carcinoma [12-14]. These results are contradictory to
the findings mentioned above that RLN node metastasis
is an unfavorable prognostic factor in thoracic esopha-
geal squamous cell carcionoma. To evaluate the out-
come of curative esophagectomy treatment, as well as
the prognostic impacts of RLN node metastasis and the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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lyzed a cohort of patients with squamous cell carcinoma
of the middle esophagus admitted in our institution.
Methods
Patients
Three hundred and twenty six patients with squamous
cell carcinoma of the middle thoracic esophagus were
surgically treated at the Department of Thoracic Surgery
of Zhejiang Cancer Hospital, Hangzhou, China from
January 2003 to December 2009. Among these patients,
26 patients with R1 (microscopic residual disease) or R2
(macroscopic residual disease) resections, 48 patients
receiving preoperative therapy (chemotherapy and/or
radiotherapy), 8 patients with histories of gastric cancer,
5 patients with synchronous cancers (gastric cancer or
laryngeal cancer) and 4 patients with non-squamous
cell carcinoma of the middle thoracic esophagus were
excluded. The records of the remaining 235 patients with
curative esophagectomy were retrospectively reviewed.
Written informed consents were obtained from all
patients before surgery. The Institutional Review Board
of Zhejiang Cancer Hospital approved the study and
the need for individual patient consent was waived.
The cohort of patients included 194 males and 41
females with an average age of 58 ranging from 37 to
79 years old. Preoperative evaluation included endoscopy
with biopsy, barium swallow examination, computerized
tomography of the chest and upper abdomen, andFigure 1 Lymphadenectomy for esophageal carcinoma. (a) Upper abd
artery, LGA: left gastric artery. (b) Right upper mediastinal field. SA: subclav
upper mediastinal field. RLN: (left) recurrent laryngeal nerve, AA: aotic arch,
internal jugular vein, RLN: (left) recurrent laryngeal nerve, black arrow: anasultrasound of the neck. Pulmonary and cardiac function
tests were routinely performed to assess medical operabil-
ity. Histological diagnosis of each of the patients was
established before treatment. Tumor location, grade, and
stage were defined according to the 7th edition of UICC
TNM classification [15]. Recurrent laryngeal nerve palsy
and the presence of clinical supraclavicular or cervical
nodal involvement were considered a contraindication
for surgery.
In our institution, two types of lymphadenectomy
were performed for esophageal cancer depending on the
operators’ surgical preference. Four surgeons performed
2-field lymphadenectomy, while 2 performed 3-field
lymphadenecotmy as a chief operator.
Surgical procedure
A transthoracic esophagectomy was performed for each
of the 235 patients with either a 2-field or a 3-field
lymphadenectomy. The surgical procedure of esopha-
gectomy with 2-field lymphadenectomy was described
previously [16]. In principle, this procedure consisted of
esophagectomy with total mediastinal lymphadenectomy
through a right thoracotomy, and upper abdominal
lymphadenectomy through an upper median laparot-
omy. Total mediastinal lymphadenctomy was performed
according to the classification defined by the International
Society for Diseases of the Esophagus (ISDE) [17]. The
extent of lymphadenectomy involved dissection of the
bilateral RLNs, paratracheal, brachiocephalic artery,ominal field. CA: celiac artery, CHA: common hepatic artery, SA: splenic
ian artery, RLN: (right) recurrent laryngeal nerve, T: trachea. (c) Left
T: trachea. (d) Left cervical field: TCA: transverse cervical artery. IJV:
tomotic site.
Table 1 Clinicopathological features of the 235 patients
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to the middle and lower mediastinal nodes. Upper
abdominal lymphadenectomy was performed to include
the paracardial, lesser curvature, left gastric, common
hepatic, celiac, and splenic nodes. The 3-field lymphad-
enectomy included cervical lymphadenectomy of the
paraesophageal, deep cervical, and supraclavicular nodes in
addition to 2-field lymphadenectomy performed through
a collar cervical incision. Esophageal anastomosis was
performed in the neck for each patient (Figure 1). Gastro-
intestinal continuity reconstruction was achieved by stom-
ach bypass in 233 patients and by colon conduit in 2
patients. After surgery, the anatomical location of the
removed nodes were labeled by the operating surgeon,
and then histologically examined with hematoxylin and
eosin staining.
Follow-up
Complete follow-up information was available for all
patients. Survival time was defined as the period from
the date of surgery till death (including surgical related
death and non-cancer related death) or the most recent
follow-up in March 2013. The duration of follow-up
ranged from 1 month to 131 months (average 45 months,
median 37 months). One hundred and sixty four patients
died, and the remaining 71 were still alive at the last
contact.
Statistical analysis
Survival curves were constructed using Kaplan-Meier
method [18], and log-rank test was used to determine
significance [19]. To confirm the optimal cutoff value
for the number of metastatic lymph nodes, the Cox pro-
portional hazard model was used to compare survival
rates between the groups with fewer and more meta-
static lymph nodes [20]. The number of metastatic
lymph nodes with the highest χ2 value was regarded as
the optimal cutoff level. The influence of each clinico-
pathological variable on survival was assessed using Cox
proportional hazard model. A P value of less than 0.05
was considered statistically significant.
Results
Clinicopatholgoical features
Clinicopathological features of the patients are sum-
marized in Table 1. Of the 235 patients, 159 underwent
2-field and 76 underwent 3-field lymphadenectomy. The
majority of patients had T3 disease (157 patients, 67%).
Among the 8 patients with T4 tumors, invasions to the
lungs were diagnosed in 3 patients, and invasions to the
pericardia were diagnosed in 5 patients. A total of 102
patients had no lymph node metastases (43%), and 133
patients had lymph node metastases (57%). Mediastinal
and abdominal lymph node metastases were found in124 (53%) and 46 (20%) patients respectively. Cervical
lymph node metastases were found in 23 of 76 (30%)
patients who underwent 3-field lymphadenectomy. Of
the 133 patients with nodal involvement, 81 (61%) had
metastatic RLN nodes and 52 (39%) had at least one
positive node but no RLN nodal involvement. The mi-
nority of patients (56 patients, 24%) received adjuvant
therapy postoperatively.
Table 2 Cutoff values for the number of metastatic lymph
nodes analyzed by Cox proportional hazard model
Cut-off values χ2 Hazards ratio (95% CI) P value
1 vs. ≥2 2.758 1.457 (0.932-2.278) 0.099
2≤ vs. ≥3 5.706 1.599 (1.084-2.359) 0.018
3≤ vs. ≥4 4.042 1.486 (1.008-2.191) 0.046
4≤ vs. ≥5 8.854 1.804 (1.209-2.692) 0.004
5≤ vs. ≥6 19.610 2.542 (1.658-3.898) <0.001
6≤ vs. ≥7 20.903 2.820 (1.774-4.482) <0.001
7≤ vs. ≥8 15.544 2.269 (1.597-4.330) <0.001
8≤ vs. ≥9 6.543 2.070 (1.171-3.660) 0.012
9≤ vs. ≥10 6.696 2.189 (1.191-4.023) 0.012
10 ≤ vs. ≥11 2.698 1.766 (0.888-3.514) 0.105
Wu et al. BMC Surgery 2014, 14:43 Page 4 of 10
http://www.biomedcentral.com/1471-2482/14/43The number of metastatic lymph nodes and its
stratification
The number of metastatic lymph nodes of the 133
patients ranged from 1 to 32, with a mean of 4.4 and a
median of 3. The Cox proportional hazards regression
model revealed that the most significant difference in
survival was identified with a cutoff value of six meta-
static lymph nodes, yielding a χ2 value of 20.903, aFigure 2 Survival curves of patients with various number of metastat
nodes, P < 0.001; with ≤ 6 metastatic nodes vs. with ≥ 7 metastatic nod
metastatic nodes, P < 0.001).hazard ratio of 2.820, and a 95% confidence interval of
1.774-4.482 (Table 2).
Survival
The median survival for all patients was 37 months, and
the 1-, 3- and 5-year survival rates were 79%, 51%, and
39%, respectively. The Kaplan-Meier curves constructed
using the optimal values for the number of metastatic
lymph nodes are shown in Figure 2. The median survival
time of patients without lymph node metastasis, with ≤ 6
metastatic lymph nodes, and with ≥ 7 metastatic lymph
nodes were 83, 30 and 11 months, respectively. There
were significant differences between patients without
lymph node metastasis and with ≤ 6 metastatic lymph
nodes (P < 0.001), between patients without lymph node
metastasis and with ≥ 7 metastatic lymph nodes (P < 0.001),
and between patients with ≤ 6 metastatic lymph nodes
and with ≥ 7 metastatic lymph nodes (P < 0.001).
Survival curves based on lymph node status are shown
in Figure 3. The median survival time of node-negative
patients, node-positive patients without RLN nodal
involvement and RLN node-positive patients were 83,
24 and 24 months, respectively. There were significant
differences between node-negative patients and RLNic nodes (without lymph node metastasis vs. with ≤ 6 metastatic
es, P < 0.001; without lymph node metastasis vs. with ≥ 7
Figure 3 Survival curves of patients with different RLN node status (without lymph node metastasis vs. with RLN nodal involvement,
P < 0.001; without lymph node metastasis vs. node-positive without RLN nodal involvement, P < 0.001; with RLN nodal involvement vs.
node-positive without RLN nodal involvement, P = 0.979).
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negative patients and node-positive patients without
RLN nodal involvement (P < 0.001). There was no sig-
nificant difference between RLN node-positive patients
and node-positive patients without RLN nodal involve-
ment (P = 0.979).
Furthermore, the difference in survival time of pa-
tients with ≤ 6 metastatic lymph nodes was insignificant
between RLN node-positive patients and node-positive
patients without RLN nodal involvement. Similarly,
the difference in survival between the two groups
mentioned above and patients with ≥ 7 metastatic
lymph nodes was also insignificant (P = 0.804) (P =
0.143) (Figure 4).
In addition, survival curves based on N stages ac-
cording to the 7th edition of UICC TNM classification
are shown in Figure 5. The median survival time of N0,
N1, N2, and N3 patients were 83, 32, 24, and 11 months
respectively. There was a significant difference in sur-
vival time among all these patients (P < 0.001). How-
ever, the difference in survival time was insignificant
between N1 and N2 patients (P = 0.869).Univariate and multivariate analyses for
clinicopathological variables
In a univariate analysis for survival, T category (P < 0.001),
node status (P < 0.001), lymphatic and venous invasion
(P = 0.001), intramural metastasis (P = 0.009) and adju-
vant therapy (P = 0.034) were significantly associated
with overall survival (Table 3). Because three methods
(N stage, number of metastatic nodes, RLN node me-
tastasis) were used in stratifying N status, three Cox
models were constructed to avoid problems with the
presence of multicollinearity. As shown in Table 4, the
number of positive nodes (P < 0.001) were identified as
a significant factor associated with overall survival,
while RLN node metastasis was not a prognostic predi-
cator (P = 0.865). In a model with stratification by N
stage, N2 stage was insignificantly associated with over-
all survival (P = 0.722).
RLN node status and the type of lymphadenectomy
In the 81 patients with RLN node metastasis, the differ-
ence in survival rate was insignificant between 2-field
and 3-field lymphadenectomy (P = 0.843). In the other
Figure 4 Survival curves of patients with various number of metastatic nodes and different recurrent laryngeal nerve node status
(≤ 6 nodes + RLN + vs. ≤ 6 nodes + RLN-, P = 0.928; ≥ 7 nodes + RLN- vs. ≥ 7 nodes + RLN+, P = 0.520).
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did not differ significantly between 2-field and 3-field
lymphadenectomy (P = 0.661).
Discussion
Here we demonstrated that the presence of RLN node
metastasis was not a prognostic predicator in node-
positive patients with squamous cell carcinoma of the
middle thoracic esophagus. A previous report including
55 patients with esophageal squamous cell carcinoma
who underwent esophagectomy with 2-field lymphde-
nectomy showed that RLN node metastasis was the
strongest prognostic predicator [11]. That report was
more heterogeneous in term of tumor site: tumors were
located below and above the carina in 40 and 15 pa-
tients, respectively [11]. Different tumor sites might lead
to different frequencies of lymph node metastasis. In thatreport, frequencies of RLN node metastasis was 18% in all
patients (10/55) and 26% (10/34) in node-positive patients
[11]. While in our study, the frequencies of RLN node
metastasis were 34% (81/235) in all patients and 62%
(81/133) in node-positive patients. More importantly,
Authors only performed univariate analysis, but did not
perform multivariate analysis in that cohort [11]. Dealing
with data this way may cause confounding effect that
influenced the interpretation of results. There was
another report on clinical outcomes of 106 patients
with esophageal squamous cell carcinoma who under-
went 3-field lymphadenectomy [3]. Univariate and
multivariate analyses indicated that RLN node metasta-
sis was the most unfavorable prognostic factor [3]. In
that series, 10, 67 and 29 patients had tumors located
in the upper, middle and lower thoracic esophagus,
respectively. Although RLN node metastasis occurred
Figure 5 Survival curves of patients with different N stages (N0 vs. N1, P < 0.001; N0 vs. N2, P < 0.001; N0 vs. N3, P < 0.001; N1 vs. N2,
P = 0.869; N1 vs. N3, P < 0.001; N2 vs. N3, P < 0.001).
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not state how many patients with lesions in the middle
thoracic esophagus had RLN node metastasis. Further-
more, the factor of the number of metastatic lymph
nodes was not included in the analysis [3].
Among various possible prognostic predicator of esopha-
geal carcinoma, the importance of number of metastatic
nodes has been widely recognized [1,10,11,13,21]. Pa-
tients with a large number of metastatic nodes had a
lower average survival rate than those with less meta-
static nodes. Stratification of the number of metastatic
nodes varied in different reports (for example, 1–3 vs ≥ 4
[11,13], 1–4 vs ≥ 5 [10], 1–5 vs ≥ 6 [21], and 1–7 vs ≥ 8
[1]). Our report showed that the survival rate de-
creased with an increasing number of metastatic nodes,
and that the optimal cutoff value was between 1–6 and ≥ 7
metastatic nodes. On the other hand, there was little
evidence supporting that the site of metastatic nodes
influenced the prognosis of esophageal carcinoma
[14,22,23]. For example, celiac node metastasis, which
was regarded as M1 disease in the past, did not meanpoor prognosis in node-positive patients with esophageal
cancer [22,23]. It was found that for middle and lower
thoracic esophageal carcinoma, survival of patients with
celiac node metastasis did not differ from those with left
gastric node metastasis [23]. The 7th edition of TNM
staging system also has redefined a regional node of
esophageal cancer as any periesophageal lymph nodes
from cervical nodes to celiac nodes; yet N staging has
already been subclassfied according to the number of
metastatic nodes [15].
The frequency of RLN node metastasis was reported
between 20% and 50% in patients with squamous cell
carcinoma of the upper and middle thoracic esophagus
[1,2,4,8]. In our institution, upper thoracic tumor is rou-
tinely treated with radiotherapy-dominated multidiscip-
linary therapy. Some authors pointed out that RLN was
the initial metastatic site (including micrometastatic site)
in esophageal squamous cell carcinoma [6,7]. Others found
that the histology of RLN node was characterized by
large cortical area without anthracosis and hyaliniza-
tion, which suggests a high filtration activity [5]. All
Table 3 Univariate analysis of 235 patients with










< 60 132 78 52 40 37
≥ 60 103 81 51 37 42
Sex 0.206
Male 194 79 50 38 36
Female 41 71 59 43 60
Differentiation 0.080
G1 49 88 55 49 45
G2 143 81 53 40 42
G3 43 65 40 36 24
T category <0.001*
T1/T2 70 91 71 62 86
T3/T4 165 74 42 29 29
Node status <0.001*
N0 102 92 71 60 83
N1 57 77 46 24 32
N2 49 78 39 26 24
N3 27 37 11 7 11
Node status <0.001*
N0 102 92 71 60 83
N + RLN- 52 71 35 19 24
N + RLN+ 81 68 37 22 24
Node status <0.001*
N0 102 92 71 60 83
≤ 6 positive
nodes (N+)
106 77 43 25 30
≥ 7 positive
nodes (N+)




No 190 82 56 42 44




No 220 81 53 40 42




No 179 79 53 44 46




2-field 159 80 54 41 45
3-field 76 78 45 35 33
*Variables were also used for multivariate analysis.
Table 4 Multivariate analysis for 133 node-positive
patients with squamous cell carcinoma of the middle
thoracic esophagus
Variables Hazard ratio 95% CI P value
Model 1
N1 1.000 (reference)
N2 1.084 0.696-1.688 0.722
N3 3.135 1.877-5.236 <0.001
Model 2
N + RLN- 1.000 0.865
N + RLN+ 1.035 0.693-1.548
Model 3
≤ 6 positive nodes (N+) 1.000 (reference) <0.001
≥ 7 positive nodes (N+) 3.022 1.888-4.837
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tigated. Some authors found that the prognoses of
patients with RLN node metastasis was better in the
three-field lymphadenectomy group than in the two-field
lymphadenectomy group, while in patients without RLN
node metastasis, there was no significant differences in
survival between these two groups [8]. Their results could
not be duplicated in this study. It should be noted that the
features of patients in that study including age, tumor
location and disease stage, differed between patients
with RLN node metastasis and those without RLN node
metastasis [8]. These differences between patients groups
could cause biased results. Frequency of cervical nodal
metastasis (30%) in this report was similar to previous
reported. Significant associations between RLN node
metastasis and cervical node metastasis in esophageal
squamous cell carcinoma were emphasized by many
authors, and they firmly believed that 3-field lymphade-
nectomy was indicated if RLN node metastasis happens
[4,8-10]. But there is lack of high-level evidence sup-
porting 3-field lymphadenectomy in terms of long-term
survival [13,24,25]. Instead it is certain that increased
postoperative morbidity and impaired long-term quality
of life are associated with 3-field lymphdenectomy
[24,25]. Although 3-field lymphadenectomy might offer
survival benefit for selected patients with esophageal
cancer, the controversy over the optimal extent of lymph-
adenectomy still exists [25,26]. For a majority of patients
there would be no arguments about performing two-field
lymphadenectomy to offer a balance between benefits and
risks. In addition, the emphasis of three-field lymphad-
enectomy lies more in RLN lymphadenectomy than in
cervical lymphadenectomy [24]. In this study, 3-filed
lymphadenetomy did not show its survival benefits
compared with 2-field lymphadenectomy, but RLN
node metastasis also did not portend a worse prognosis
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cluding dissection of RLN nodes is strongly supported.
Several potential shortcomings of the present study
are worth mentioning. This retrospective study from a
single institution suffers from the typical biases associ-
ated with such studies. The choice of surgical proce-
dures depended on surgeons’ preference without strict
criteria. It is likewise unavoidable that lymphadenec-
tomy was performed in more or less different extent by
different surgeons. In addition, there was no set stand-
ard for patients to receive adjuvant therapy. As shown
in the result of the univariate analysis, patients with
adjuvant therapy had worse survival than those with-
out adjuvant therapy. The majority of patients with
adjuvant therapy had a large number of metastatic
nodes (data not shown). However, this series was proved
to be homogenous in clinical variables including tumor
site and pathologic type. Further multi-institutional
studies with larger sample size are needed to confirm
these results.
Conclusions
RLN lymph node metastasis is not a prognostic predictor
in node-positive patients with squamous cell carcinoma of
the middle thoracic esophagus. However, the number of
metastatic nodes is a key prognostic predictor. Systemic
lymphadenectomy including dissection of RLN nodes is
therefore necessary for these patients.
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